Buy Cytoxan (Cyclophosphamide) Online — Bristol-Myers Squibb Foundational Alkylating Chemotherapy for Lymphomas, Leukemias, Breast Cancer & Autoimmune Disease

Two very different worlds of Cytoxan use

Cancer chemotherapy. The original use. Cytoxan is part of dozens of chemotherapy regimens including CHOP for non-Hodgkin lymphoma, AC for breast cancer, induction regimens for acute leukaemia, and conditioning for stem cell transplant. Given at high doses in intermittent cycles.

Severe autoimmune disease. The second life of the drug. Cytoxan controls life-threatening lupus nephritis, ANCA-associated vasculitis (GPA and MPA), severe systemic sclerosis, and refractory rheumatological conditions. Given at lower doses either as monthly IV pulses or daily oral tablets.

The alkylating agent story

Cyclophosphamide is an inactive prodrug. When you swallow a tablet or receive an IV infusion, the molecule enters the bloodstream but does nothing yet. It travels to the liver.

In the liver, the cytochrome P450 enzyme system (mainly CYP2B6, CYP3A4, CYP2C19) converts cyclophosphamide into an active metabolite called 4-hydroxycyclophosphamide. This spontaneously breaks down into two fragments: phosphoramide mustard (the main cytotoxic actor) and acrolein (the main troublemaker in the bladder).

Phosphoramide mustard binds DNA and creates crosslinks between the two DNA strands. Cells that try to divide when their DNA is crosslinked cannot complete replication and die. Fast-dividing cells are hit hardest.

Why fast-dividing cells are the target and the collateral damage

Cancer cells divide rapidly and cannot repair DNA crosslinks fast enough. They die. This is the intended effect. But other rapidly dividing tissues take collateral damage in the same window:

• 🔴 Bone marrow - white cells, red cells, platelets all drop
• 🔴 Hair follicles - alopecia within 2-3 weeks
• 🔴 Gut lining epithelium - nausea, mucositis, diarrhoea
• 🔴 Reproductive tissue - egg and sperm precursors damaged, sometimes permanently
• 🔴 Bladder urothelium - not fast-dividing but hit by acrolein directly (see Section 19)

Pharmacokinetics that shape dosing

The main cancer uses

• Non-Hodgkin lymphoma - the C in R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). The workhorse first-line regimen for aggressive B-cell lymphomas including DLBCL. Section 5 covers this.
• Hodgkin lymphoma - part of some second-line or transplant conditioning regimens. First-line HL is now dominated by ABVD or BEACOPP.
• Breast cancer - the C in AC (doxorubicin + cyclophosphamide), TAC (docetaxel added), and CMF (older regimen). Used in early-stage adjuvant, neoadjuvant, and metastatic settings. Section 6 covers this.
• Multiple myeloma - part of some VCD (bortezomib, cyclophosphamide, dexamethasone) and other combinations, especially in resource-limited settings
• Acute lymphoblastic leukaemia (ALL) - included in some induction and consolidation regimens
• Chronic lymphocytic leukaemia (CLL) - historically part of FCR (fludarabine, cyclophosphamide, rituximab); newer targeted drugs now often replace this
• Paediatric cancers - neuroblastoma, retinoblastoma, Ewing sarcoma, rhabdomyosarcoma, Wilms tumour - Cytoxan features in many childhood cancer protocols
• Ovarian cancer - historically part of CAP; less used now
• Small cell lung cancer - historically part of CAV; largely replaced
• Stem cell transplant conditioning - high-dose Cytoxan (60-120 mg/kg over 2-4 days) either alone or with total body irradiation to prepare the bone marrow before autologous or allogeneic transplant

Why Cytoxan endures across generations of newer drugs

Many newer oncology drugs (targeted agents, immunotherapy, CAR-T cells, antibody-drug conjugates) have entered practice since Cytoxan launched in 1959. Some cancers where Cytoxan was standard 30 years ago now have entirely different treatments. But cyclophosphamide has kept its place because it is cheap, orally and IV available, well characterised, works through a mechanism that is hard to build resistance against, and combines well with almost everything. In lymphoma and breast cancer especially, the newer drugs are usually added alongside Cytoxan rather than replacing it.

What the multi-drug combinations look like

Understanding your regimen name helps decode what will happen:

• R-CHOP = Rituximab + Cyclophosphamide + Hydroxydaunorubicin (doxorubicin) + Oncovin (vincristine) + Prednisone; every 21 days for 6 cycles
• AC = Adriamycin (doxorubicin) + Cyclophosphamide; every 14-21 days, usually 4 cycles
• TAC = Taxotere (docetaxel) + Adriamycin + Cyclophosphamide; every 21 days
• CMF = Cyclophosphamide + Methotrexate + 5-Fluorouracil; older breast cancer regimen still used in specific contexts
• FCR = Fludarabine + Cyclophosphamide + Rituximab; older CLL regimen
• VCD = Bortezomib (Velcade) + Cyclophosphamide + Dexamethasone; myeloma

The main autoimmune uses

• Lupus nephritis, particularly proliferative class III/IV - the kidney disease of systemic lupus. Cytoxan induction has been standard since the NIH lupus trials of the 1980s. Section 7 covers this.
• ANCA-associated vasculitis - granulomatosis with polyangiitis (GPA, formerly Wegener), microscopic polyangiitis (MPA), and eosinophilic granulomatosis (EGPA). Cyclophosphamide or rituximab are the two main induction options. Section 8 covers this.
• Severe systemic sclerosis with interstitial lung disease - Cytoxan has trial-level evidence for lung function stabilisation
• Neuropsychiatric lupus and other severe SLE manifestations
• Rare and refractory rheumatological conditions - some cases of Behcet disease, refractory dermatomyositis, severe autoimmune cytopenias
• Nephrotic syndrome that has failed steroids - especially some paediatric cases
• Severe pemphigus vulgaris and pemphigoid - rare, when other drugs fail

How autoimmune Cytoxan differs from cancer Cytoxan

• Lower doses - typically 500-1000 mg/m? IV pulses or 1-2 mg/kg/day orally versus higher cancer doses
• Time-limited induction - usually 3-6 months of Cytoxan, then switch to a less toxic maintenance drug (mycophenolate, azathioprine, methotrexate, rituximab)
• Total cumulative dose matters - lifetime cyclophosphamide exposure is capped because bladder cancer risk climbs with cumulative dose
• Pulse regimens preferred where possible - monthly IV pulses give lower total exposure than daily oral
• Rituximab has replaced Cytoxan in many previously Cytoxan-treated conditions - especially ANCA vasculitis after the RAVE and RITUXVAS trials in 2010

The modern positioning shift

Since 2010, rituximab has substantially replaced cyclophosphamide as first-line induction for ANCA-associated vasculitis in many centres. Mycophenolate mofetil has similarly become first-line for lupus nephritis in many contexts. Cyclophosphamide remains the answer when these newer drugs fail, are unavailable, or when the disease is severe enough to warrant maximum immunosuppression. In young clients particularly, the fertility damage from Cytoxan makes teams reach for alternatives first when they exist.

R-CHOP - the standard regimen

Each cycle is delivered on day 1, then a 20-day break before the next cycle. Six to eight cycles total, depending on stage and response.

• 💉 Rituximab 375 mg/m? IV - CD20 antibody
• 💉 Cyclophosphamide 750 mg/m? IV - alkylating agent
• 💉 Doxorubicin 50 mg/m? IV - anthracycline
• 💉 Vincristine 1.4 mg/m? IV (max 2 mg) - vinca alkaloid
• 💊 Prednisone 100 mg oral days 1-5

Cure rates worth knowing

R-CHOP cures 60-70 percent of clients with newly diagnosed DLBCL. That is a real cure - long-term remission with no evidence of disease, comparable to any other cancer with equivalent staging. This is why the intensity is justified. Without R-CHOP most DLBCL clients would die of the lymphoma within a year or two.

R-CHOP variants and alternatives

• R-CHOP-14 vs R-CHOP-21 - 14-day cycles with G-CSF versus 21-day cycles; similar outcomes in most studies
• DA-R-EPOCH - dose-adjusted regimen for double-hit or high-risk lymphomas; adds etoposide, uses continuous infusion
• R-CVP - similar but without doxorubicin; used for indolent lymphomas or when anthracycline is contraindicated (severe cardiac disease)
• Pola-R-CHP - polatuzumab vedotin substituting for vincristine; approved for high-risk DLBCL after POLARIX trial (2021)
• Bendamustine + rituximab (BR) - alternative for indolent NHL; no cyclophosphamide

What each cycle looks like practically

Day 1 is the infusion day. You come to the day-treatment unit or infusion centre. Pre-medication with antihistamines, paracetamol, sometimes hydrocortisone. Rituximab first (2-4 hours the first time, faster later). Then cyclophosphamide, doxorubicin, vincristine as pushes or short infusions. Prednisone tablets to take home for days 1-5. Anti-nausea drugs (ondansetron, dexamethasone) before and for a few days after.

Days 7-14 are the nadir period when white blood cells and platelets are lowest. Blood tests around this time. Watch for fever, bruising, mouth ulcers. Growth factors (filgrastim, pegfilgrastim) often given prophylactically. Recovery by day 21. Then next cycle.

Red flags during R-CHOP

• 🔴 Fever above 38 C - neutropenic fever until proven otherwise; emergency
• 🔴 Any new bleeding, bruising, or petechiae
• 🔴 Severe mouth ulceration preventing eating
• 🔴 Persistent vomiting or diarrhoea over 24 hours
• 🔴 Blood in urine - possible bladder toxicity, see Section 19
• 🔴 New severe breathlessness - cardiac or infection concern

The main breast cancer regimens with Cytoxan

What AC therapy actually looks like

A typical AC cycle:

• 💉 Doxorubicin 60 mg/m? IV as a short push - the "red devil" the nurses will warn you about
• 💉 Cyclophosphamide 600 mg/m? IV as a 15-30 minute infusion
• Anti-nausea premedication with 5-HT3 antagonist plus dexamethasone plus NK1 antagonist for the highly emetogenic combination
• Cycles every 14 or 21 days for typically 4 cycles
• G-CSF (filgrastim, pegfilgrastim) support in most modern protocols
• Followed by a taxane (paclitaxel weekly for 12 weeks, or docetaxel every 3 weeks for 4) in AC-T

HER2-positive breast cancer

If your breast cancer is HER2-positive, expect trastuzumab and often pertuzumab added on top of chemotherapy. Common regimens include TCH (docetaxel + carboplatin + trastuzumab) which does NOT contain cyclophosphamide, or AC-TH (AC followed by taxane + trastuzumab) which does. The team will pick based on individual factors and trial data.

Cardiac issue with AC - the anthracycline part

The cardiac toxicity you may hear about with AC is from the doxorubicin, not the cyclophosphamide. Cumulative anthracycline dose over about 400-450 mg/m? increases risk of anthracycline cardiomyopathy. Baseline echocardiogram or MUGA scan measures ejection fraction. Repeat during therapy in some protocols. TC regimen (docetaxel + cyclophosphamide, no anthracycline) is offered to clients with cardiac concerns.

Which lupus nephritis needs Cytoxan

Lupus nephritis is classified by kidney biopsy into six classes. Cytoxan is used for the aggressive classes:

• Class III (focal proliferative) - Cytoxan or mycophenolate as first-line induction
• Class IV (diffuse proliferative) - the most severe; Cytoxan or mycophenolate as first-line induction
• Class V (membranous) with nephrotic-range proteinuria - Cytoxan is one option
• Mixed III/V or IV/V - same as pure III or IV
• Classes I and II (mesangial) do NOT need Cytoxan
• Class VI (advanced sclerosis) is usually beyond immunosuppression - focus shifts to dialysis and transplant

Two Cytoxan protocols

NIH regimen (higher-dose): monthly IV pulses of 500-1000 mg/m? for 6 months, then quarterly for 2 more years. Higher cumulative dose. More effective for severe disease. More fertility toxicity.

Euro-Lupus regimen (lower-dose): six fortnightly IV pulses of 500 mg fixed dose. Total cumulative dose only 3 g. Equally effective as the NIH regimen for European populations. Now the preferred approach in many centres for its lower toxicity profile - especially fertility.

Cytoxan vs mycophenolate mofetil

Mycophenolate mofetil (MMF) has emerged as the main alternative to Cytoxan for lupus nephritis induction. The ALMS trial compared them head-to-head - similar efficacy overall, with some suggestion MMF works particularly well in non-Caucasian populations. MMF has less fertility toxicity, no bladder cancer risk, and is oral rather than IV. It has become first-line in many centres. Cytoxan is still preferred when disease is severe, when MMF has failed, or when the client cannot afford MMF (which is more expensive in some settings).

The induction-maintenance sequence

Cytoxan is only for induction - typically 3-6 months. After that, therapy switches to maintenance with mycophenolate mofetil or azathioprine, which are less toxic drugs given orally for months or years. Nobody stays on Cytoxan long-term in lupus. The point is to knock down the acute flare, then hand over to safer drugs.

Newer options changing the picture

• Voclosporin (Lupkynis) - approved 2021 as add-on to MMF; better remission rates in trials
• Belimumab (Benlysta) - approved for SLE and now for lupus nephritis as add-on
• Anifrolumab (Saphnelo) - type I interferon receptor blocker; adjunctive therapy
• These newer drugs are usually added to standard therapy rather than replacing Cytoxan or MMF directly

The classical Cytoxan-based induction (Fauci regimen)

Anthony Fauci and colleagues at NIH established the classical AAV regimen in the 1970s: daily oral Cytoxan 2 mg/kg plus daily prednisolone. This transformed AAV from a nearly universally fatal disease into a manageable chronic condition. It remained standard for four decades until pulse IV Cytoxan and rituximab emerged as alternatives.

The CYCLOPS trial changed practice

The CYCLOPS trial published in 2009 compared daily oral cyclophosphamide with monthly IV pulses. Result: pulse cyclophosphamide was as effective at inducing remission with substantially lower cumulative dose. Bladder cancer and infertility risks drop with lower cumulative exposure. Modern practice uses pulse IV Cytoxan (15 mg/kg every 2-3 weeks for 6-9 doses) as the preferred Cytoxan approach.

Rituximab arrived and reshaped the choice

The RAVE trial (NEJM 2010) and RITUXVAS trial (NEJM 2010) compared rituximab with cyclophosphamide for AAV induction. Both showed rituximab was as effective as Cytoxan and better tolerated in several respects. Rituximab does not cause bladder toxicity, does not damage fertility permanently, and has emerged as first-line induction in many centres.

Where Cytoxan still fits in AAV in 2026

• First-line induction when rituximab is unavailable or unaffordable (many low- and middle-income settings)
• First-line for severe disease with life-threatening organ involvement where the trial evidence is longer-standing with Cytoxan
• When rituximab has failed to induce remission
• When there is contraindication to rituximab (severe infusion reactions, active hepatitis B, PML history)
• Older clients where Cytoxan tolerability may be preferable to rituximab-related infection risk
• Some presentations of eosinophilic granulomatosis (EGPA) where Cytoxan retains a stronger evidence base

The induction-maintenance sequence in AAV

• Induction (3-6 months): pulse IV Cytoxan or rituximab plus tapering high-dose steroids
• Remission achieved: switch to less toxic maintenance
• Maintenance (2-5 years or longer): azathioprine, methotrexate, mycophenolate, or rituximab given periodically
• PLEX (plasma exchange) - added for severe pulmonary haemorrhage or rapidly progressive kidney failure; reduces mortality in the sickest clients
• Prophylaxis - PCP prophylaxis with co-trimoxazole; bone protection; vaccination review

Red flags in AAV

• 🔴 New haemoptysis - pulmonary haemorrhage
• 🔴 Rapid rise in creatinine - kidney flare
• 🔴 New or worsening haematuria
• 🔴 Neurological symptoms - mononeuritis multiplex, CNS lesions
• 🔴 Any fever above 38 C on Cytoxan - PCP or bacterial infection

When oral is used

• Some autoimmune induction protocols (historically Fauci regimen for AAV)
• Some low-dose maintenance regimens
• Some paediatric oncology protocols
• Some myeloma regimens
• When IV access is limited or infusion centre logistics are difficult

When IV is used

• All modern cancer chemotherapy regimens (R-CHOP, AC, TAC, TC)
• Pulse regimens for lupus nephritis (NIH or Euro-Lupus)
• Pulse regimens for AAV (CYCLOPS-style)
• Stem cell transplant conditioning (high-dose)
• Where allowed by resources - IV pulse regimens are generally preferred for their lower cumulative toxicity

Practical differences in daily life

On oral Cytoxan: you take tablets every day. Blood tests weekly to fortnightly. Attention to hydration and morning-versus-evening dosing to protect the bladder. Symptoms accumulate steadily.

On IV pulse Cytoxan: you attend the infusion centre every 2-3 weeks. Each session is a half-day event with IV hydration, mesna, and the Cytoxan infusion. Between pulses you feel more like a normal person, with side effects concentrated in the 7-14 days after each dose. Blood tests before each pulse to check nadir recovery.

Typical doses by indication

Dose adjustments the team will make

• Renal impairment - reduce dose 25-50 percent for eGFR under 30-45 mL/min
• Older adults - often reduce IV pulses to 500 mg/m? instead of higher
• Low white cell count - hold or reduce next cycle if neutrophils below 1.5
• Low platelets - hold or reduce if platelets below 100
• Liver impairment - reduce dose in significant hepatic dysfunction
• Prior severe toxicity - infection, bladder toxicity, cardiac event - trigger dose reduction or discontinuation

Cumulative lifetime dose considerations

Bladder cancer risk climbs with lifetime cumulative cyclophosphamide dose. In autoimmune care especially, teams track cumulative exposure over years. Above about 36 grams total lifetime dose, bladder cancer risk rises measurably. Above 100 grams the risk is very high. Modern autoimmune protocols are designed to keep total exposure well below these thresholds by using pulse regimens, time-limiting therapy, and switching to less toxic maintenance drugs.

Day 0 - the day before or morning of

• Baseline blood tests: FBC, U&E, LFTs, urinalysis
• Baseline ECG in older clients or if any cardiac history
• Confirm hydration status; light meal, avoid alcohol
• Anti-nausea premedication may start the evening before for highly emetogenic regimens

Day 1 - infusion day (IV Cytoxan)

• Arrive at the infusion centre. IV cannula placed.
• Pre-medication: antihistamine, dexamethasone, 5-HT3 antagonist (ondansetron or granisetron), sometimes NK1 antagonist (aprepitant)
• IV hydration starts before Cytoxan and continues after - 1-2 litres of normal saline over the infusion period
• Mesna given before Cytoxan for high-dose regimens - see Section 12
• Cyclophosphamide infused over 15-60 minutes depending on dose
• Other drugs in the regimen follow (rituximab, doxorubicin, vincristine, etc.)
• Post-infusion hydration until you have urinated well
• Home with take-home anti-emetics and instruction sheet

Days 1-3 after infusion

Nausea is often the most noticeable symptom. Modern anti-emetics have made this much better than it used to be, but some people still feel unwell for a few days. Fatigue builds. Appetite drops. Constipation is common (partly from anti-emetics). Push oral fluids to protect the bladder - drink 2-3 litres of water daily for the first 3-4 days.

Days 7-14 - the nadir

Blood counts reach their lowest around days 10-14. White cells lowest, platelets low, red cells drift lower. This is the vulnerable window for:

• 🔴 Fever above 38 C = neutropenic fever = emergency; go to hospital same day
• 🔴 Bruising or bleeding = platelet check needed
• 🔴 Mouth ulcers = mucositis; supportive care
• 🔴 Any new symptom = call the treating team, not the GP

Days 14-21 - recovery

Blood counts start climbing back. Energy returns. Appetite improves. Hair may start thinning around week 2-3 - full alopecia over the first month (Section 18). Weekly blood tests confirm recovery. Preparation for the next cycle begins.

Emergency contact rules

You will be given 24-hour emergency contact numbers for your treating team. Use them. Do not go to a general emergency department without informing the team first if possible - chemotherapy clients need specific triage that non-oncology emergency staff may miss. Fever, bleeding, breathlessness, severe pain, or any new severe symptom during the first two weeks after Cytoxan needs the oncology team's eyes on it.

The mechanism recap

Acrolein, a toxic aldehyde by-product of cyclophosphamide metabolism, concentrates in urine. In the bladder it damages the urothelial lining causing acute hemorrhagic cystitis and, over cumulative exposure, raising bladder cancer risk. Dilute urine reduces acrolein concentration. Mesna binds acrolein in the bladder and neutralises it.

Hydration - the client's job

• 💧 Drink 2-3 litres of water daily for 3-4 days starting the day before each cycle
• 💧 Empty your bladder every 2-3 hours during the day - do not let urine sit
• 💧 Empty bladder at bedtime and once during the night if possible
• 💧 Take oral Cytoxan in the morning, not evening - urine sitting in bladder overnight is more concentrated
• 💧 Extra fluids include water, weak tea, diluted juice - avoid alcohol
• 💧 Watch urine colour - clear pale yellow is target

Mesna - the drug protection

Mesna (mercaptoethane sulfonate) is a bladder-protective agent given with high-dose Cytoxan (typically over 600 mg/m? for IV, or above certain cumulative thresholds). Mesna binds acrolein in the bladder and inactivates it.

• Given IV or orally
• Total dose usually 60 percent of the cyclophosphamide dose, split across the day
• One dose before Cytoxan; further doses 4 and 8 hours after
• Standard for high-dose regimens (transplant conditioning, some sarcoma protocols)
• Not routinely used for lower-dose autoimmune pulse regimens (Euro-Lupus 500 mg fixed dose does not always require mesna if hydration is adequate)

Red flags for bladder trouble

• 🔴 Blood in urine - any amount, at any time during or after Cytoxan
• 🔴 Burning or pain on urination
• 🔴 Urgency, frequency without infection
• 🔴 Blood clots in urine - emergency
• 🔴 Inability to pass urine - urgent

Any of these need urgent contact with the treating team. Bladder toxicity can be acute (hemorrhagic cystitis - Section 19) or long-term (bladder cancer years later - Section 21).

General diet rules on Cytoxan

• 🍽️ Small frequent meals beat large meals - graze 6 times a day
• 🍽️ Bland foods when nauseated - crackers, toast, rice, banana, chicken broth
• 🍽️ Cold foods often tolerate better than hot - smell is less pronounced
• 🍽️ Ginger tea or ginger sweets help mild nausea for many
• 🍽️ Adequate protein - lean meat, fish, eggs, dairy, tofu; maintain muscle
• 🍽️ Well-cooked food only during nadir period - raw fish, raw egg, soft cheese, undercooked meat avoided due to infection risk in neutropenic period
• 🍽️ Wash all fruit and vegetables well; peel where possible during nadir
• 🍽️ Avoid buffet food, food left at room temperature, unpasteurised dairy

Neutropenic diet - the safer eating guide

Traditional strict neutropenic diet has softened somewhat in recent guidelines but the principles remain useful for the nadir period (days 7-14 after each cycle):

Safer choices:

• 🟢 Cooked meat, fish, eggs (well done)
• 🟢 Pasteurised dairy
• 🟢 Peelable fruit (banana, orange, mango)
• 🟢 Cooked vegetables
• 🟢 Sealed packaged foods

Avoid or minimise during nadir:

• 🔴 Sushi, sashimi, raw fish
• 🔴 Rare or undercooked meat
• 🔴 Runny eggs, homemade mayonnaise
• 🔴 Soft or blue cheese, unpasteurised dairy
• 🔴 Salad bars, buffets, food left out
• 🔴 Deli meats and pate
• 🔴 Untested tap water in unfamiliar locations

Grapefruit and CYP3A4

Cyclophosphamide is metabolised by CYP3A4 (among others). Large amounts of grapefruit inhibit this enzyme and can theoretically affect drug levels. Practical impact is uncertain but avoiding daily grapefruit juice during Cytoxan therapy is sensible. Occasional grapefruit slice or single glass - fine.

Nutrition support

If eating becomes difficult, ask for a dietitian referral - cancer centres have oncology dietitians. Nutritional supplements (Ensure, Fortisip, Fresubin) provide calories and protein when solid food is unappealing. Weight loss during chemotherapy affects tolerability and outcomes; maintaining muscle mass matters.

Position on alcohol during active Cytoxan

• 🔴 Abstinence is the safest position during active chemotherapy cycles
• 🔴 No alcohol for 24-48 hours around each Cytoxan infusion - drug clearance window
• 🔴 No alcohol during the nadir period (days 7-14) - hepatic and infection stress adds up
• 🟡 Occasional light drinking (a small glass of wine) may be acceptable between cycles for stable clients on lower-dose autoimmune regimens - discuss with treating team
• 🔴 No alcohol if LFTs are raised
• 🔴 No alcohol if you also take paracetamol regularly - combined liver load

The nausea and hydration angle

Alcohol worsens nausea in the days after Cytoxan and undermines the hydration effort that protects your bladder. Even if the liver angle were not important, the nausea and dehydration effects alone would argue for abstinence around treatment cycles.

Non-alcoholic drink choices

• 🟢 Water (aim for 2-3 litres/day on cycle days)
• 🟢 Weak tea, herbal tea
• 🟢 Diluted fruit juice
• 🟢 Coconut water for taste variety
• 🟢 Non-alcoholic beer or wine - fine if you enjoy them
• 🟡 Coffee in moderation is acceptable - not more than 2-3 cups/day
• 🔴 Avoid energy drinks (cardiovascular stress + caffeine load)

Very common (over 30 percent of clients)

• 🟡 Nausea and vomiting - dose-related; managed with modern anti-emetics; Section 17
• 🟡 Myelosuppression - low white cells, platelets, red cells; Section 16
• 🟡 Alopecia (hair loss) - dose-related; Section 18
• 🟡 Fatigue - can be marked in the days after each cycle
• 🟡 Immunosuppression and infection susceptibility

Common (10-30 percent)

• 🟡 Mucositis - mouth ulcers, difficulty swallowing
• 🟡 Diarrhoea or constipation
• 🟡 Fertility damage - dose-related; Section 20
• 🟡 Amenorrhoea in women
• 🟡 Elevated liver enzymes - Section 23
• 🟡 Skin rash
• 🟡 Bladder irritation - burning, urgency; Section 19

Less common (1-10 percent)

• 🟠 Hemorrhagic cystitis - can be dramatic; Section 19
• 🟠 Cardiac toxicity at high doses; Section 22
• 🟠 Interstitial pneumonitis and pulmonary fibrosis
• 🟠 SIADH - low sodium from inappropriate ADH release
• 🟠 Skin pigmentation changes, nail changes
• 🟠 Blurred vision, tearing

Rare but serious - emergency contact

• 🔴 Neutropenic fever (temp above 38 C with low white cells) - hospital immediately
• 🔴 Massive hemorrhagic cystitis with clots
• 🔴 Cardiac arrhythmia or acute heart failure at high-dose regimens
• 🔴 Anaphylaxis - facial swelling, difficulty breathing
• 🔴 Progressive multifocal leukoencephalopathy (PML) - very rare CNS infection
• 🔴 Encephalopathy - confusion, seizures
• 🔴 Tumour lysis syndrome at cycle 1 in high-burden disease

Long-term effects to know about

• Secondary malignancies - myelodysplasia, AML, bladder cancer, solid tumours; Section 21
• Permanent infertility - especially in men, in women over 35, and at higher cumulative doses; Section 20
• Cardiomyopathy at high cumulative doses
• Chronic bladder changes
• Ovarian failure and early menopause

The nadir pattern

• Neutrophils (white cells) - lowest around days 7-14 after each cycle; recover by day 21-28
• Platelets - lowest around days 10-16; recover slower than neutrophils
• Red cells and haemoglobin - drift down cumulatively across cycles, slower recovery
• Lymphocytes - drop and stay down for months after high-dose regimens, contributing to opportunistic infection risk

Neutropenic fever is an emergency

During the nadir period, any fever above 38 C is a medical emergency. Bacterial or fungal infections can progress from mild to septic shock within hours in a neutropenic client. Action required:

• 🔴 Do not wait to see if it settles
• 🔴 Call the 24-hour oncology team number immediately
• 🔴 Go to hospital same day - most centres have a rapid-access chemo emergency pathway
• 🔴 Broad-spectrum IV antibiotics within one hour of arrival
• 🔴 Blood cultures, chest X-ray, urinary sample - source hunt
• 🔴 Admission until neutrophils recover and cultures clear

Preventive strategies

• G-CSF support (filgrastim, pegfilgrastim) - often given after each cycle to boost white cell recovery; reduces nadir severity
• PCP prophylaxis with co-trimoxazole - prevents Pneumocystis pneumonia in high-risk clients
• Antiviral prophylaxis - aciclovir if prior herpes zoster, or if lymphocyte counts very low
• Antifungal prophylaxis in specific high-risk settings (transplant conditioning)
• Hand hygiene and mask in crowded settings during nadir
• Avoid ill contacts, crowds during nadir where possible

Anaemia and platelet issues

If haemoglobin drops significantly, blood transfusion is used. Erythropoiesis-stimulating agents (epoetin, darbepoetin) are used cautiously in specific cancer settings. Platelet transfusions for platelet counts below 10 x10^9/L or below 20 with active bleeding. Watch for bruising, petechiae, nose bleeds, gum bleeding, and unusually heavy periods - all warrant platelet count check.

The three time windows of nausea

• Acute (0-24 hours) - worst during and immediately after infusion; managed with pre-treatment 5-HT3 antagonists and steroid
• Delayed (24-96 hours) - can be worse than acute for Cytoxan; managed with NK1 antagonist and continued 5-HT3 blockade
• Anticipatory (before cycle) - learned response after prior bad experiences; benzodiazepines or CBT approach

The modern anti-emetic combination

For highly emetogenic Cytoxan-containing regimens (AC, TAC, R-CHOP, transplant conditioning), current guidelines recommend:

• 💉 5-HT3 antagonist - ondansetron, granisetron, or palonosetron
• 💉 NK1 antagonist - aprepitant, fosaprepitant, or netupitant/palonosetron combination
• 💉 Dexamethasone - potent anti-emetic in this context
• 💊 Olanzapine 5-10 mg as add-on has proven benefit in trials - increasingly common in protocols
• 💊 Rescue anti-emetics - metoclopramide, prochlorperazine, cyclizine for breakthrough nausea
• 💊 Benzodiazepines (lorazepam) for anticipatory nausea

What clients can do

• 🟢 Take anti-emetics on schedule, not just when nauseated - prevention beats rescue
• 🟢 Small frequent meals - Section 13
• 🟢 Cold foods often tolerate better - smell is less intense
• 🟢 Ginger tea or ginger sweets for mild nausea
• 🟢 Acupressure wristbands (Sea-Bands) help some clients
• 🟢 Cannabinoids (nabilone, dronabinol) - specialist prescription; effective in some clients
• 🟢 Adequate hydration - dehydration worsens nausea
• 🟢 Avoid strong smells - perfume, cooking smells, some foods
• 🟢 Fresh air and rest between meals

When to call the team

• 🔴 Persistent vomiting beyond 24 hours despite anti-emetics
• 🔴 Cannot keep fluids down for 24 hours
• 🔴 Signs of dehydration - dry mouth, reduced urine, dizziness
• 🔴 Vomiting with fever
• 🔴 Vomiting blood or coffee-ground material
• 🔴 Severe abdominal pain with vomiting

The alopecia timeline

• Days 14-21 after first cycle: hair starts thinning, coming out on brush and pillow
• Weeks 3-4: substantial hair loss including eyebrows, eyelashes, body hair
• Through completion of chemotherapy: full alopecia in most
• 2-3 months after last cycle: new hair growth begins
• 6 months post-therapy: substantial regrowth, often with different texture initially
• 12 months post-therapy: usually full return to pre-chemotherapy hair

Practical preparation

• 💚 Cut hair shorter before it starts falling - some clients shave head early to control the transition
• 💚 Wig fitting - many centres arrange this before hair loss starts so the wig matches natural colour
• 💚 Head scarves, hats, headbands - practical alternatives to wigs
• 💚 Skin care for bald scalp - sunscreen, moisturiser
• 💚 Cotton pillowcases - reduce friction during hair loss period
• 💚 Gentle shampoo, no heat styling during regrowth

Scalp cooling

Cold caps (scalp cooling systems) worn during and after infusion reduce blood flow to hair follicles and can reduce hair loss substantially. Available at many cancer centres. Not free everywhere. Uncomfortable but effective for many. Not appropriate for haematological cancers or scalp involvement. Discuss with the treating team.

Regrowth notes

New hair often comes back with different characteristics for the first 6-12 months - curlier or straighter, sometimes different colour, often finer or coarser. This usually normalises over 1-2 years. Occasional persistent alopecia occurs, especially after high-dose regimens or in combination with taxanes (docetaxel is associated with rare persistent alopecia). Ask about this if it matters to you.

Acute hemorrhagic cystitis

Acrolein damages the bladder urothelium. The classical presentation:

• 🔴 Blood in urine - visible red or brown
• 🔴 Pain and burning on urination
• 🔴 Urgency and frequency
• 🔴 Suprapubic pain
• 🔴 In severe cases - clot retention, need for continuous bladder irrigation

Emergency signs

• 🔴 Heavy bleeding with clots in urine
• 🔴 Inability to pass urine
• 🔴 Severe suprapubic pain
• 🔴 Signs of anaemia from blood loss
• 🔴 Fever with the urinary symptoms - possible infection on top

Any of these need same-day urology assessment. Severe cases may require catheterisation, continuous bladder irrigation, cystoscopy with cauterisation, or in very severe cases surgical intervention.

Rates and risk factors

• Overall cystitis rate: 5-40 percent depending on regimen intensity and mesna/hydration use
• High-dose regimens (transplant conditioning): risk highest without mesna
• Prior pelvic radiotherapy - substantially increased risk
• Concurrent BCG or other bladder irritant
• Inadequate hydration during and after infusion
• Delayed bladder emptying (nighttime)
• Cumulative dose over 36 g associated with much higher risk of cystitis and later cancer

Long-term bladder cancer risk

Cyclophosphamide is a known human bladder carcinogen - IARC Group 1 classification. Bladder cancer risk climbs with cumulative dose:

• Below 20 g cumulative: risk modest above baseline
• 20-50 g cumulative: risk elevated 5-10 fold
• Above 50 g cumulative: substantial lifelong risk requiring surveillance
• Onset typically 5-15 years after exposure
• Risk persists indefinitely - lifetime concern

Long-term surveillance

• Yearly urinalysis for microscopic haematuria in high-cumulative-dose clients
• Any macroscopic haematuria years after Cytoxan needs cystoscopy - not "wait and see"
• Ultrasound or CT urogram in high-risk clients per specialist review
• Note the exposure permanently in your medical record - future doctors need to know

The fertility picture

In men: Cytoxan damages germ cells directly. Sperm counts often drop to zero (azoospermia) after even moderate cumulative doses. Recovery is variable. High-dose or long-course therapy often causes permanent infertility.

In women: Cytoxan damages ovarian follicles. Younger women (under 30) recover ovarian function more often; women over 40 usually enter permanent early menopause. Risk climbs with cumulative dose:

• Under 30 years old: 20-30 percent permanent ovarian failure
• 30-40 years old: 40-60 percent permanent ovarian failure
• Over 40 years old: 80-90 percent permanent ovarian failure

Fertility preservation options - arrange BEFORE first cycle

For men:

• 💉 Sperm banking - simple, quick, effective; 1-3 samples over a few days before starting chemotherapy
• 💉 Ask at diagnosis; most cancer centres refer to a fertility clinic within days

For women:

• 💉 Embryo cryopreservation - if in partnership; ovarian stimulation + IVF + freezing; takes 2-3 weeks
• 💉 Oocyte (egg) freezing - similar to embryo but without fertilisation; option for single women
• 💉 Ovarian tissue cryopreservation - surgical option for children and when time is short
• 💉 GnRH agonist during chemotherapy - may reduce ovarian damage; some trial evidence; discuss with team

The timing problem

Fertility preservation typically requires 2-3 weeks. In cancer therapy, this delay is usually acceptable and worth arranging. In severe autoimmune disease requiring urgent Cytoxan induction (severe vasculitis, life-threatening lupus flare), delay may not be possible. If treatment absolutely cannot wait, GnRH agonist during chemotherapy is the fallback option for women, and post-therapy testicular sperm extraction (TESE) may be an option for men.

Contraception during and after therapy

• Both men and women need reliable contraception during Cytoxan and for at least 6-12 months after
• Cytoxan is teratogenic - pregnancy during exposure carries severe fetal harm risk
• Even if fertility is impaired, pregnancy remains possible - do not rely on chemotherapy-induced infertility as contraception
• Barrier methods, IUDs (copper or hormonal), or hormonal contraception depending on individual situation
• Discuss with oncology or rheumatology team - some hormonal options are avoided in specific cancers

The main secondary cancers linked to Cytoxan

• 🔴 Bladder cancer - the most specific risk; onset 5-15 years after exposure; dose-related
• 🔴 Myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) - alkylator-type secondary MDS/AML; onset 3-10 years after exposure
• 🟡 Non-Hodgkin lymphoma - modestly elevated in some cohorts
• 🟡 Skin cancers - non-melanoma types elevated in immunosuppressed cohorts
• 🟡 Other solid tumours - modest overall increase in cancer risk across the lifespan

Bladder cancer risk in detail

• Standardised incidence ratio of 4-7 fold overall for Cytoxan-exposed clients
• Higher for oral daily regimens than IV pulse regimens (cumulative dose driver)
• Higher without adequate hydration and mesna
• Risk persists for decades - a client treated at 40 remains at elevated risk at 65
• Aggressive smoking multiplies the risk

MDS/AML - alkylator-related secondary leukaemia

Alkylating agents (including Cytoxan) cause a specific type of secondary MDS or AML with poor prognosis. Onset 3-10 years after exposure. Preceded by cytopenias and characteristic chromosomal changes (5q- or 7q- most common). Risk climbs with cumulative dose and is worse when combined with other alkylators (melphalan, chlorambucil) or radiotherapy.

What surveillance looks like

• Yearly full blood count - watch for cytopenias suggesting MDS
• Yearly urinalysis for haematuria - watch for bladder cancer
• Any macroscopic haematuria years after therapy - cystoscopy, not watchful waiting
• Any unexplained cytopenia - refer to haematology promptly
• Skin surveillance - especially in immunosuppressed autoimmune clients
• Standard age-appropriate cancer screening - do not skip mammograms, colonoscopy, cervical smears; you are more not less at risk
• Smoking cessation - the single biggest modifiable risk factor
• Sun protection for skin cancer prevention

The risk-benefit calculation

Secondary cancer risk from Cytoxan is real but must be weighed against the near-term benefit. In someone whose lymphoma would be fatal without R-CHOP, a 2 percent lifetime bladder cancer risk 15 years later is acceptable. In someone with mild autoimmune disease where alternatives exist, that same risk is much harder to justify. This is why modern practice pushes for lower cumulative doses and preferred use of rituximab or mycophenolate where they work.

The two cardiac patterns

High-dose acute cardiotoxicity: at doses over 120 mg/kg (transplant conditioning), Cytoxan can cause acute heart failure or hemorrhagic myocarditis. Onset within days to 1-2 weeks of infusion. Presents as new heart failure, arrhythmia, or, rarely, cardiogenic shock.

Standard dose cardiotoxicity: at doses used in R-CHOP, AC, TC, and autoimmune regimens, Cytoxan itself has minimal direct cardiac effect. The cardiac worries with these regimens are usually from the doxorubicin (anthracycline) partner, not Cytoxan.

Baseline cardiac assessment before Cytoxan

• ECG at baseline
• Echocardiogram or MUGA scan to measure ejection fraction - especially if regimen includes anthracycline
• BP measurement
• Fasting lipids and glucose in longer-term autoimmune therapy
• Prior cardiac history: previous MI, cardiomyopathy, valvular disease - discuss with cardio-oncology

Cardiac warning signs - urgent

• 🔴 New severe breathlessness, especially lying flat
• 🔴 New ankle swelling
• 🔴 Chest pain
• 🔴 Palpitations or irregular rhythm
• 🔴 Fainting or near-fainting
• 🔴 Sudden weight gain from fluid retention

Cardio-oncology support

Major cancer centres have cardio-oncology clinics for clients on cardiotoxic chemotherapy. If you have prior heart disease or if your regimen includes anthracycline plus Cytoxan, ask about cardio-oncology referral for baseline and ongoing assessment. Modern strategies include ACE inhibitors or beta-blockers preventively in some cases, choice of less cardiotoxic regimens (TC without anthracycline instead of AC-T), and dexrazoxane cardioprotection in specific circumstances.

Long-term cardiac survivorship

After chemotherapy completion, cardiac risk persists lifelong especially if anthracyclines were part of the regimen. Standard cardiovascular prevention - BP control, lipid management, smoking cessation, regular exercise, healthy diet - matters more, not less. Cancer survivorship clinics include cardiac review in most centres.

Common liver findings on Cytoxan

• Mild-to-moderate elevated ALT/AST in 15-25 percent
• Cholestatic pattern (elevated ALP, bilirubin) less common
• Serious hepatotoxicity in under 1 percent
• Veno-occlusive disease (sinusoidal obstruction syndrome) - specific to high-dose conditioning; rare in standard chemotherapy

Standard monitoring schedule

• Baseline LFTs before starting
• Before each IV pulse or cycle
• During any active symptomatic period
• Weekly on daily oral therapy for the first month, then every 2-4 weeks
• Full liver panel yearly during long-term follow-up

Liver warning signs

• 🔴 Jaundice - yellowing of skin or eyes
• 🔴 Dark tea-coloured urine
• 🔴 Pale putty-coloured stools
• 🔴 Right upper abdominal pain
• 🔴 Persistent nausea, loss of appetite disproportionate to typical chemo effect
• 🔴 Unusual bruising or bleeding
• 🔴 Itching without rash

Serious - avoid or manage carefully

• 🔴 Live vaccines - contraindicated during and shortly after Cytoxan; risk of severe infection
• 🔴 Warfarin - Cytoxan can prolong INR; more frequent monitoring
• 🔴 Allopurinol - increases Cytoxan bone marrow toxicity
• 🔴 Digoxin - reduced absorption
• 🔴 Succinylcholine anaesthesia - prolonged apnoea due to reduced pseudocholinesterase
• 🔴 Other alkylators or radiotherapy - additive marrow, bladder, and secondary cancer risk

Moderate - inform prescriber

• Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) - variable effect on active metabolite
• Strong CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, St John's Wort) - variable effect
• Immunosuppressants combined (mycophenolate, azathioprine, tacrolimus, ciclosporin) - additive infection risk
• Thiazide diuretics - added myelosuppression
• Other cardiotoxic drugs (anthracyclines already discussed; also trastuzumab)
• NSAIDs - platelet function and kidney risk

Usually safe together

• Inactivated vaccines (flu, pneumococcal, COVID) - see Section 30
• Paracetamol at standard doses
• Most antibiotics (except allopurinol interaction above)
• Standard antihypertensives
• Statins
• Anti-emetics used in supportive care
• G-CSF and other supportive care agents

Oral daily Cytoxan

• Within 12 hours of usual time: take the missed dose now
• More than 12 hours late: skip it, take the next dose at usual time
• Never double up
• Missed several days: contact the treating team
• Cannot swallow due to mucositis: contact the team - IV alternative or dose adjustment

IV pulse Cytoxan

• Missed appointments for IV infusion are usually rescheduled within days
• Call the infusion centre if you cannot attend a scheduled appointment
• Delays of a few days rarely affect cumulative outcome
• Delays of weeks may need review with the team - disease control considerations

The bigger adherence picture

Cytoxan therapy is not indefinite. Cancer regimens have defined cycles. Autoimmune induction usually runs 3-6 months. If you are struggling with adherence because of side effects, that is a treating team conversation - dose reduction, better supportive care, or switching to alternative therapy are options.

Fetal effects of Cytoxan exposure

First-trimester exposure causes:

• Major congenital malformations - skull, limb, eye, palate, cardiac
• Miscarriage
• Fetal growth restriction

Second and third trimester exposure causes:

• Fetal growth restriction
• Neonatal cytopenias and infection at birth
• Long-term developmental concerns

Contraception rules

• Women: reliable contraception during and for at least 12 months after last Cytoxan dose
• Men: reliable contraception during and for at least 6 months after last dose - sperm damage recovery time
• Barrier plus another method often recommended
• Copper or hormonal IUDs for longer-acting reliability
• Do not rely on chemotherapy-induced infertility as contraception - fertility can persist even when significantly impaired

Cancer diagnosed during pregnancy

Rarely, cancer is diagnosed during pregnancy requiring urgent chemotherapy. Cytoxan-containing regimens can be given after the first trimester in some cancers - modern registries suggest reasonable neonatal outcomes for second/third trimester exposure to standard regimens. This is a specialist decision made with a multidisciplinary team including maternal-fetal medicine. It is not a routine choice.

If you find you are pregnant on Cytoxan

1. Contact the treating team immediately
2. Do not stop Cytoxan without medical guidance
3. Referral to maternal-fetal medicine specialist
4. Discussion of continuation vs termination based on gestational age and cancer/disease
5. If continuing, intensive fetal monitoring throughout

The rule

• 🔴 Do not breastfeed during Cytoxan therapy
• 🔴 Wait at least 36 hours after the last dose before resuming breastfeeding for oral daily therapy (some sources say longer)
• 🔴 For IV pulse regimens, wait 1-2 weeks after each pulse before breastfeeding, but by the time of the next pulse the exposure has recurred - so breastfeeding is not really compatible with pulse regimens either
• 🔴 Most practical: discontinue breastfeeding entirely before starting Cytoxan

Practical steps

• If actively breastfeeding when Cytoxan is proposed, discuss weaning
• Milk suppression options available if needed - cabergoline usually first-line
• Formula feeding or expressed milk from a donor bank as alternative
• Pediatrician awareness of the situation

Common dose adjustments in older adults

• Reduce IV pulses by 25-50 percent in clients over 70-75
• Renal function-based dosing - creatinine clearance guides adjustment
• Fixed 500 mg pulse regimen (Euro-Lupus) often chosen over higher m? dosing
• Modified R-CHOP - R-mini-CHOP for very elderly lymphoma clients
• More cautious use of anthracyclines in combination
• Growth factor support almost mandatory

Comprehensive geriatric assessment

Many cancer centres perform CGA in older cancer clients before deciding on chemotherapy intensity. The G8, VES-13, and full geriatric assessment identify frailty domains - functional, cognitive, nutritional, social - that affect chemotherapy tolerance. Frail clients may benefit from reduced-intensity regimens or non-chemotherapy alternatives.

Specific concerns in older adults

• Higher infection risk from lower baseline immune reserves
• Cardiovascular comorbidity worsening chemotherapy tolerance
• Polypharmacy interactions
• Cognitive change complicating self-care
• Falls risk from fatigue and cytopenias
• Nutrition and hydration harder to maintain
• Life expectancy considerations affecting risk-benefit

Main paediatric uses

• Acute lymphoblastic leukaemia (ALL) - part of induction and consolidation regimens
• Non-Hodgkin lymphoma - part of paediatric NHL protocols
• Neuroblastoma - dose-intensive induction
• Wilms tumour - specific high-risk protocols
• Rhabdomyosarcoma - VAC and modified regimens
• Ewing sarcoma - VDC and related regimens
• Steroid-resistant nephrotic syndrome - specific paediatric use
• Severe paediatric SLE and juvenile vasculitis

Paediatric-specific considerations

• Long lifespan magnifies late effects - secondary cancers, fertility, cardiac all matter more
• Growth and development - can be affected
• Fertility preservation - prepubertal options (ovarian/testicular tissue) discussed at diagnosis
• Age-appropriate consent and information
• Family and school integration during long treatment courses
• Long-term follow-up in survivorship clinics - lifelong for late effect monitoring

Live vaccines - contraindicated

Live attenuated vaccines can cause severe disseminated infection in immunosuppressed clients:

• 🔴 MMR (measles, mumps, rubella)
• 🔴 Varicella (chickenpox)
• 🔴 Live shingles vaccine (Zostavax - now largely replaced by inactivated Shingrix)
• 🔴 Yellow fever
• 🔴 BCG
• 🔴 Oral polio (rarely used now)
• 🔴 Live influenza (nasal spray) - use injectable inactivated instead
• 🔴 Oral typhoid
• 🔴 Rotavirus

Avoid during and for at least 3-6 months after finishing Cytoxan.

Inactivated vaccines - recommended

These are safe and important:

• 🟢 Annual flu vaccine (inactivated injection)
• 🟢 Pneumococcal (PCV13 and PPV23)
• 🟢 Meningococcal (ACWY and B)
• 🟢 COVID-19 vaccines
• 🟢 Shingrix (recombinant zoster) - safe for immunosuppressed
• 🟢 Hepatitis B (if not already immune)
• 🟢 HPV in appropriate age groups
• 🟢 Tdap - tetanus, diphtheria, pertussis

Timing tips

• If possible, vaccinate before starting Cytoxan - immune response is better
• If already on therapy, still worth giving inactivated vaccines - reduced but real response
• Some centres re-vaccinate 6-12 months after finishing Cytoxan to restore protection
• Family and close contacts should be up to date on vaccines including MMR and varicella
• Household members receiving live vaccines - discuss with team; usually fine but ask

The emergency rule

Fever above 38 C during the nadir period is an emergency. Call the 24-hour oncology number and go to hospital same day. Do not wait, do not self-medicate with antipyretics, do not assume it will settle.

Non-neutropenic infections during between-cycle recovery periods are less urgent but still warrant contact with the team, especially if fever, severe symptoms, or progressive worsening.

Common infections during Cytoxan therapy

• Bacterial: chest, urine, skin, gut, IV line infections; treated with broad-spectrum IV antibiotics initially
• Fungal: candida (mouth, oesophagus, systemic), aspergillus in high-risk clients
• Viral: herpes zoster reactivation, CMV in transplant clients, respiratory viruses
• Pneumocystis jirovecii pneumonia (PCP) - prevented by co-trimoxazole prophylaxis in high-risk protocols
• Progressive multifocal leukoencephalopathy (PML) - rare but reported with prolonged immunosuppression

Prevention basics

• 🟢 Hand hygiene - most important single intervention
• 🟢 Avoid ill contacts during nadir
• 🟢 Mask in crowded settings during nadir
• 🟢 Neutropenic diet during nadir (Section 13)
• 🟢 PCP prophylaxis where indicated
• 🟢 Aciclovir prophylaxis for HSV or VZV history
• 🟢 Antifungal prophylaxis in high-risk protocols
• 🟢 Skin care - keep dry, treat any cuts promptly
• 🟢 Dental care before starting - defer major dental work during therapy
• 🟢 Vaccinations as in Section 30

Non-infectious sick day rules

• Vomiting or diarrhoea unable to keep fluids down: call the team
• Chest pain, breathlessness, palpitations: urgent
• Severe headache or confusion: urgent
• Severe abdominal pain: urgent
• Any new severe symptom: err on the side of calling

Absolute contraindications

• Known hypersensitivity to cyclophosphamide or its metabolites
• Pregnancy (see Section 26; exceptions in second/third trimester cancer treatment under specialist care)
• Breastfeeding without weaning first
• Active severe infection - treat infection first
• Severe bone marrow suppression at baseline (neutrophils under 1.5 or platelets under 100 depending on indication)
• Severe hemorrhagic cystitis or bladder outflow obstruction
• Active bladder cancer

Relative contraindications - use with care

• Severe renal or hepatic impairment
• Recent live vaccine within 4 weeks
• History of prior alkylator-induced secondary cancer
• Cumulative dose approaching lifetime limits
• Severe cardiovascular disease at high-dose regimens
• Uncontrolled active tuberculosis or hepatitis B
• Recent major surgery
• Uncontrolled diabetes with concurrent steroid therapy

Storage of oral tablets

• Room temperature under 25 C, in original packaging
• Not in bathroom - humidity degrades
• Keep away from children and pets - cytotoxic drug
• Some centres advise handling with gloves for cytotoxic waste rules
• Do not use past expiry date
• Return unused tablets to pharmacy - special cytotoxic waste stream

Travel during and after Cytoxan

• During active chemotherapy: avoid non-essential travel; infection risk higher; alter regimen difficult
• Pack tablets in hand luggage in original packaging with pharmacy letter
• Time zone changes: shift oral dosing gradually
• Vaccinations: no live vaccines - discuss travel destinations with team well in advance
• Travel insurance: declare cancer or serious autoimmune disease
• Long-haul flights: DVT risk stacked with underlying disease; discuss
• Take a copy of your treatment record for medical use abroad

Surgery on Cytoxan

• Tell every surgeon and anaesthetist
• Major surgery usually deferred until blood counts recover
• Succinylcholine anaesthesia caution (Section 24)
• Wound healing impaired during active therapy
• Infection risk higher post-op
• Coordinate with treating team on timing

Yearly review during long-term survivorship

After finishing Cytoxan therapy, ongoing surveillance continues for years:

• Yearly full blood count - watch for MDS/AML
• Yearly urinalysis for haematuria - bladder cancer surveillance
• Any macroscopic haematuria at any time = cystoscopy
• Cardiac assessment if anthracycline was part of regimen
• Bone density if long steroid course
• Fertility assessment if considering conception - discuss with team
• Age-appropriate cancer screening (mammogram, colonoscopy, cervical screening) continued or intensified
• Skin surveillance
• Cumulative dose recorded permanently in medical file
• Late effects clinic referral where available

A closing thought

Cytoxan is one of the most consequential drugs in modern medicine. It cures cancers that would otherwise be fatal. It rescues clients from disease that would otherwise destroy kidneys or blood vessels. It also carries some of the most serious side effects and long-term risks of any prescription drug. Approaching it with respect - understanding the mechanism, sticking with the hydration and monitoring rules, using every supportive care option available, flagging symptoms early - makes the therapy manageable. The team looking after you has done this many times. Ask questions, use the emergency lines, and hold on through the cycles. The far side is worth reaching.